Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
12 January 2024 - 8:05AM
Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases,
today announced the closing of its previously announced
underwritten public offering of 19,722,500 shares of its common
stock at a public offering price of $17.50 per share, which
includes 2,572,500 shares issued upon the exercise in full by the
underwriters of their option to purchase additional shares of
common stock in the offering. The gross proceeds to Dyne from the
offering were approximately $345.1 million, before deducting
underwriting discounts and commissions and offering expenses
payable by Dyne. All of the shares in the offering were sold by
Dyne.
Morgan Stanley, J.P. Morgan, Jefferies and Stifel acted as joint
book-running managers for the offering. Oppenheimer & Co. and
Raymond James acted as co-managers for the offering.
The offering was made pursuant to a shelf registration statement
on Form S-3 that was previously filed with and declared effective
by the Securities and Exchange Commission (“SEC”) and a related
registration statement that was filed with the SEC on January 4,
2024 pursuant to Rule 462(b) under the Securities Act of 1933 (and
became automatically effective upon filing). The offering was made
only by means of a prospectus supplement and accompanying
prospectus that form a part of the registration statements. A final
prospectus supplement relating to and describing the terms of the
offering has been filed with the SEC and may be obtained for free
by visiting the SEC’s website at www.sec.gov. Copies of the final
prospectus supplement and accompanying prospectus may also be
obtained by contacting: Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014, or by email at prospectus@morganstanley.com; J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204,
or by email at prospectus-eq_fi@jpmchase.com; Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by
email at Prospectus_Department@Jefferies.com; or Stifel, Nicolaus
& Company, Incorporated, Attention: Prospectus Department, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720 or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases. With its
proprietary FORCE™ platform, Dyne is developing modern
oligonucleotide therapeutics that are designed to overcome
limitations in delivery to muscle tissue. Dyne has a broad pipeline
for serious muscle diseases, including clinical programs for
myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy
(DMD) and a preclinical program for facioscapulohumeral muscular
dystrophy (FSHD).
Contacts:
InvestorsAmy Reillyareilly@dyne-tx.com
857-341-1203
MediaStacy
Nartkersnartker@dyne-tx.com781-317-1938
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dyne Therapeutics (NASDAQ:DYN)
Historical Stock Chart
From Sep 2023 to Sep 2024